NCT04908514已完成2 期
A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects With Plaque Psoriasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Change From Baseline in the Psoriasis Area and Severity Index (PASI)
研究概览
简要总结
A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Plaque Psoriasis
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is a male or non-pregnant female 18 years of age or older.
- •Subject has provided written informed consent.
- •Females must be post-menopausal, surgically sterile, or use a highly effective method of birth control during the trial and for 30 days after the last administration of test article. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test (UPT) at Visit 1/Screening and Visit 2/Baseline.
- •Male subjects who are not surgically sterile (e.g., vasectomy performed at least 6 months prior to trial entry) and are sexually active with a female partner who is of childbearing potential must agree to use an effective form of birth control for the duration of the trial and for 90 days after completion of treatment.
- •Subject, in the investigator's opinion, is in good general health and free of any disease state or physical condition that might impair evaluation of plaque psoriasis or exposes the subject to an unacceptable risk by trial participation.
排除标准
- •Subject is pregnant, lactating, or is planning to become pregnant during the trial.
- •Subject has a physical condition which, in the investigator's opinion, might impair evaluation of plaque psoriasis or which exposes the subject to an unacceptable risk by trial participation.
- •Subject is currently enrolled in an investigational drug, biologic, or device trial.
- •Subject has used an investigational drug, investigational biologic, or investigational device treatment within 30 days prior to Visit 2/Baseline.
研究组 & 干预措施
ADX-629 250 mg administered orally twice daily (BID) for approximately 12 weeks.
Experimental
干预措施: ADX-629 (Drug)
结局指标
主要结局
Change From Baseline in the Psoriasis Area and Severity Index (PASI)
时间窗: The efficacy assessment period was baseline, Week 4, Week 8, and Week 12. Baseline was the day prior to randomization.
The change from baseline for PASI score was assessed on a 0 to 72 scale (0 = none, 72 = maximum severity). Mixed model for repeated measures (MMRM) analysis was performed using change from baseline as the dependent variable, baseline as a covariate, and visit as a factor.
次要结局
- Number of Subjects With a ≥ 50% Reduction Change From Baseline for PASI Score(The efficacy assessment period was Week 1 - Week 12. Baseline was the day prior to randomization.)
- Number of Subjects With a ≥ 75% Reduction Change From Baseline for PASI Score(The efficacy assessment period was Week 1 - Week 12. Baseline was Day 1 prior to randomization.)
- Change From Baseline in the Investigator's Global Assessment (IGA)(The efficacy assessment period was baseline, Week 4, Week 8, and Week 12. Baseline was the day prior to randomization.)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical CancerCervical CancerNCT05033132Agenus Inc.
终止
2 期
A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract CancerBiliary Tract Cancer (BTC)NCT03790111TerSera Therapeutics LLC53
招募中
1 期
A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid TumorsMalignant Solid TumorsNCT06737731Suzhou Suncadia Biopharmaceuticals Co., Ltd.300
招募中
2 期
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BCLocally Advanced or Metastatic Breast CancerNCT06439771MediLink Therapeutics (Suzhou) Co., Ltd.180
已完成
2 期
Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid TumorsHER2-positive Solid TumorsNCT04521179Jiangsu Alphamab Biopharmaceuticals Co., Ltd102